Provention Bio (PRVB) announced positive results in a study known as "At Risk" to delay patients from gaining Type 1 diabetes (T1D). Such substantial results were presented at the Scientific Sessions of the 79th Annual American Diabetes Association ((ADA)) meeting. The bottom line is that treatment with PRV-031 (teplizumab) was able to have a significant impact on delaying the onset of Type 1 diabetes for patients. The biotech has made an impact on prevention of onset to T1D and is also currently exploring another aspect. This involves a phase 3 study for